Building a Bridge for Batten Disease

Authors

  • Melissa L. Feuerborn MD University of Kansas
  • Carla C. Keirns MD PhD MSc FACP University of Kansas Medical Center
  • Richard J. Barohn MD University of Missouri

DOI:

https://doi.org/10.17161/rrnmf.v2i4.15355

Keywords:

Batten, NCL, rare disease, advocacy, caregivers

Abstract

Background. Neuronal Ceroid Lipofuscinosis, or Batten disease, is a neurodegenerative disorder that results in seizures, vision loss, vegetative state, and premature death. This project aims to understand the value of disease organizations in the management of Batten disease progression.

Methods. Seven semi-structured interviews with caregivers of children with Batten disease were conducted at a national family conference. Also, five semi-structured telephone interviews with disease organizations were conducted, two of which were Batten disease specific.

Results. Most caregiver participants reported difficulties in getting a diagnosis. All participants reported significant benefit from involvement in the Batten Disease Support and Research Association (BDSRA) and associated family conference. Some of the most challenging aspects of care centered around a lack of in-home aid, medical equipment, and the education system. The disease advocacy organizations included Rare KC, the National Organization for Rare Disorders (NORD), Global Genes, Noah’s Hope, and Taylor’s Tale. Disease organizations encourage rare disease families to thrive by providing the bridge that connects patients, physicians, and researchers. A central organization implements an avenue for individuals to share information and meet people in the rare disease community.

Conclusions. The participants provided clear examples of the benefits families received from being involved in a rare disease organization.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

Author Biographies

  • Carla C. Keirns MD PhD MSc FACP, University of Kansas Medical Center

    Assistant Professor, History and Philosophy of Medicine, Department of Internal Medicine, Division of Palliative Medicine 

    University of Kansas Medical Center, Kansas City, Kansas

  • Richard J. Barohn MD, University of Missouri

    Neuromuscular Medicine, Psychiatry & Neurology

    University of Missouri, Columbia, Missouri

References

Griggs R, Batshaw M, Dunkle M, et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Molecular Genetics and Metabolism. 2009 Jan;96(1):20-6. DOI:10.1016/j.ymgme.2008.10.003

Nita D, Mole S, Minassian B. Neuronal ceroid lipofuscinoses. Epileptic Disorders. 2016 Sep 1;18(S2):73-88. DOI:10.11684/epd.2016.0844

Schulza A, Kohlschüttera A, Minkb J, Simonatic A, Williamsd R. NCL diseases — clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801–1806. DOI:10.1016/j.bbadis.2013.04.008

Barohn R, Dowd D, Kagan-Hallet K. Congenital Ceroid-Lipofuscinosis. Pediatric Neurology. Jan-Feb 1992;8(1):54-9. DOI:10.1016/0887-8994(92)90054-3

Freund K, Sarraf D, Mieler W, Yannuzzi L. The Retinal Atlas. Elsevier Inc. 2017;3:233-278.

Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019 Apr;33(4):315-325. DOI:10.1007/s40263-019-00620-8

Siddiq S, Wilson B, Graham I. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet Journal of Rare Diseases. 2016 Dec 7;11(1):168. DOI:10.1186/s13023-016-0548-2

Rarediseaseday.org [Internet]. Eurordis Rare Diseases Europe. c2020. Available from: https://www.rarediseaseday.org/article/what-is-rare-disease-day

Pinto D, Martin D, Chenhall R. The involvement of patient organisations in rare disease research: a mixed methods study in Australia. Orphanet Journal of Rare Diseases. 2016 Jan 12;11:2. DOI:10.1186/s13023-016-0382-6

Downloads

Published

2021-09-17

Issue

Section

New Discoveries/New Stuff (Original Research)

How to Cite

Feuerborn, M., Keirns, C., & Barohn, R. (2021). Building a Bridge for Batten Disease. RRNMF Neuromuscular Journal, 2(4), 6-11. https://doi.org/10.17161/rrnmf.v2i4.15355